Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized, Multicenter, Vehicle-Controlled Parallel Group Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis Receiving Two Weeks of Treatment

NCT01610596 is registered in ClinicalTrials.gov with Therapeutics, Inc. as lead sponsor.

NCT NCT01610596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01610596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized, Multicenter, Vehicle-Controlled Parallel Group Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis Receiving Two Weeks of Treatment
Lead sponsor
Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2011
Completion date
February 29, 2012
Enrollment
72 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis, psoriasis